Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

MicroRNA Strongly Linked to Acute Myeloid Leukemia Risk and Recovery

By BiotechDaily International staff writers
Posted on 29 May 2013
Image: Senior author Dr. Clara D. Bloomfield (Photo courtesy of Ohio State University).
Image: Senior author Dr. Clara D. Bloomfield (Photo courtesy of Ohio State University).
Overexpression of a specific microRNA (miRNA) in patients suffering from cytogenetically normal (CN) acute myeloid leukemia (AML) has been linked to lower complete remission rate as well as to shorter disease-free and overall survival.

MicroRNAs (miRNAs) are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

Investigators at Ohio State University (Columbus, USA) measured miRNA levels and expression profiles in the blood and bone marrow of obtained from 363 patients with primary CN-AML. The test population comprised 153 patients under age 60 and 210 aged 60 and over.

Results published in the May 6, 2013, online edition of the Journal of Clinical Oncology strongly linked microRNA-155 (miR-155) to the severity of the disease. Patients with high miR-155 expression were found to be about 50% less likely to achieve complete remission and to have a 60% increase in the risk of death compared to patients with low miR-155 expression.

Although high miR-155 expression was not associated with a distinct miRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML. These mechanisms included apoptosis, nuclear factor-kappaB activation, and inflammation.

Senior author Dr. Clara D. Bloomfield, professor of medicine at Ohio State University, said, “Overall, our findings indicate that miR-155 expression is a strong and independent prognostic marker in CN-AML, and they provide clinical validation of data from preclinical models that support a crucial role of miR-155 in leukemia.”

The development of drugs with antagonistic activity toward microRNAs may provide the opportunity for future therapeutic targeting of miR-155 in AML.

Related Links:
Ohio State University



Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.